Cite
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
MLA
Delaloge, Suzette, et al. “Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.” Journal of Clinical Oncology, vol. 38, no. 11, Apr. 2020, pp. 1186–97. EBSCOhost, https://doi.org/10.1200/JCO.19.01371.
APA
Delaloge, S., Piccart, M., Rutgers, E., Litière, S., van ’t Veer, L. J., van den Berkmortel, F., Brain, E., Dudek-Peric, A., Gil-Gil, M., Gomez, P., Hilbers, F. S., Khalil, Z., Knox, S., Kuemmel, S., Kunz, G., Lesur, A., Pierga, J.-Y., Ravdin, P., Rubio, I. T., & Saghatchian, M. (2020). Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. Journal of Clinical Oncology, 38(11), 1186–1197. https://doi.org/10.1200/JCO.19.01371
Chicago
Delaloge, Suzette, Martine Piccart, Emiel Rutgers, Saskia Litière, Laura J. van ’t Veer, Franchette van den Berkmortel, Etienne Brain, et al. 2020. “Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.” Journal of Clinical Oncology 38 (11): 1186–97. doi:10.1200/JCO.19.01371.